NASDAQ: UNCYUnicycive Therapeutics Inc Stock
$0.72+0.09 (+14.29%)
Updated Sep 27, 2023
UNCY Price
$0.72
Fair Value Price
N/A
Market Cap
$25.02M
52 Week Low
$0.40
52 Week High
$2.87
P/E
-0.36x
P/B
-1.29x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$29.30M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-0.83
Operating Cash Flow
-$19M
Beta
0.55
Next Earnings
Nov 9, 2023
Ex-Dividend
N/A
Next Dividend
N/A
UNCY Overview
Unicycive Therapeutics Inc., a biotechnology company, develops therapies for kidney diseases in the U.S. It is developing Renazorb, a treatment for hyperphosphatemia in patients with chronic kidney disease, and UNI 494, a treatment for Acute Kidney Injury. The company was incorporated in 2016 and is headquartered in Los Altos, CA.
Zen Score
–
Industry Average (25)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how UNCY scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
UNCY is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
UNCY is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
UNCY's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more UNCY due diligence checks available for Premium users.
Be the first to know about important UNCY news, forecast changes, insider trades & much more!
UNCY News
Valuation
UNCY price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.36x
Industry
13.5x
Market
13.45x
UNCY price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-1.29x
Industry
5.12x
UNCY's financial health
Profit margin
Revenue
$0.0
Net Income
-$3.8M
Profit Margin
0%
UNCY's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$22.9M
Liabilities
$16.1M
Debt to equity
-0.83
UNCY's short-term assets ($21.93M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
UNCY's short-term assets ($21.93M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
UNCY's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
UNCY's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$5.5M
Investing
-$12.0k
Financing
$0.0
UNCY's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
UNCY vs Biotech Stocks
Unicycive Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.